Shopping Cart 0
Cart Subtotal
USD 0

AiCuris GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company's pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

AiCuris GmbH & Co KG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

AiCuris Enters into Collaboration Agreement with Cyclenium Pharma 10

Ligand Pharma Enters into Agreement with AiCuris 11

AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 12

Licensing Agreements 14

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 14

AiCuris GmbH & Co KG-Key Competitors 16

AiCuris GmbH & Co KG-Key Employees 17

AiCuris GmbH & Co KG-Locations And Subsidiaries 18

Head Office 18

Appendix 19

Methodology 19

About GlobalData 19

Contact Us 19

Disclaimer 19


List Of Figure

List of Figures

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AiCuris Enters into Collaboration Agreement with Cyclenium Pharma 10

Ligand Pharma Enters into Agreement with AiCuris 11

AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 12

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 14

AiCuris GmbH & Co KG, Key Competitors 16

AiCuris GmbH & Co KG, Key Employees 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company's pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

AiCuris GmbH & Co KG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

AiCuris Enters into Collaboration Agreement with Cyclenium Pharma 10

Ligand Pharma Enters into Agreement with AiCuris 11

AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 12

Licensing Agreements 14

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 14

AiCuris GmbH & Co KG-Key Competitors 16

AiCuris GmbH & Co KG-Key Employees 17

AiCuris GmbH & Co KG-Locations And Subsidiaries 18

Head Office 18

Appendix 19

Methodology 19

About GlobalData 19

Contact Us 19

Disclaimer 19


List Of Figure

List of Figures

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

AiCuris GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8

AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

AiCuris Enters into Collaboration Agreement with Cyclenium Pharma 10

Ligand Pharma Enters into Agreement with AiCuris 11

AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 12

Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 14

AiCuris GmbH & Co KG, Key Competitors 16

AiCuris GmbH & Co KG, Key Employees 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS